ETV1 inhibitor takes lead in combination approach to clinical trials
MSKCC is launching a clinical trial that uses a MEK inhibitor to target ETV1 in combination with imatinib on a small group of newly diagnosed GIST patients
MSKCC is launching a clinical trial that uses a MEK inhibitor to target ETV1 in combination with imatinib on a small group of newly diagnosed GIST patients
Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.